Company / Working Capital
CANNAPHARMARX, INC. Working Capital History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$30.3M
FY2025
5-year range
-$30.3M / -$13.0M
FY2021-FY2025
Trend
-22.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 3 consecutive years, from -$13M in FY2021 to -$30M in FY2025.
Based on SEC 10-K filings.
-$30M in FY2025.
Declined from -$17M to -$30M over the past 3 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- CANNAPHARMARX, INC.'s working capital has declined for 3 consecutive years.
- In FY2025, working capital decreased 22.4% year-over-year.
- Peak working capital was recorded in FY2015.
Company context
Key Data Points
- Altman Z-Score -18.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$30.3M | -22.4% |
| FY2024 | -$24.7M | -44.9% |
| FY2022 | -$17.1M | -31.2% |
| FY2021 | -$13.0M | +23.8% |
| FY2020 | -$17.1M | -357.8% |
| FY2019 | -$3.7M | -18.3% |
| FY2018 | -$3.2M | -226.9% |
| FY2017 | -$964.3K | -0.7% |
| FY2016 | -$957.7K | -39.9% |
| FY2015 | -$684.5K | -135.3% |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026